Endovascular Engineering Secures Major Investment for PE Treatment
Endovascular Engineering, Inc. (E2) has successfully completed a significant round of funding, raising $42 million in an oversubscribed Series B financing. This investment is aimed at advancing the company’s next-generation clot removal technology platform, specifically designed for tackling venous thromboembolism (VTE).
Collaborative Efforts and Investor Confidence
The financing round was co-led by esteemed entities such as 415 Capital and S3 Ventures, with additional participation from several notable investors, including Panakès Partners and M&L Healthcare. Santé Ventures, a founding investor, also showed strong support. Two global strategic investors joined in making substantial commitments, alongside Cordis, reinforcing their strategic partnership with E2.
Accelerating Innovation in Pulmonary Embolism Treatment
This capital infusion is set to expedite E2's mission to enhance treatment options for pulmonary embolism (PE), a serious condition arising from blood clots in the lungs. As the company approaches the completion of patient recruitment for its ENGULF pivotal trial, which aims to evaluate the H?lo PE Thrombectomy System, the additional funds solidify E2's role in meeting critical needs in interventional medicine and pave the way for a new standard of care.
Leadership Insights on Future Trajectories
Dan Rose, CEO of E2, expressed his enthusiasm, stating, "This financing represents more than capital – it validates our technology platform and positions us to revolutionize PE treatment." He's confident in establishing the H?lo PE System as a premier choice in mechanical thrombectomy for pulmonary embolism, underscoring the strong backing from the investors involved.
Advancing Clot Removal Technology
Dr. Ruben Osnabrugge of 415 Capital emphasized the unique position of E2, highlighting that, "E2 is developing a best-in-class therapy for PE, which is notably the third leading cause of cardiovascular death worldwide. Their innovative technology aligns seamlessly with our objectives to foster novel cardiovascular therapies, and we are privileged to support E2 as it pushes the H?lo PE Thrombectomy platform toward FDA approval."
Board Appointments Mark New Era
In a further demonstration of commitment and expertise, E2 recently announced the addition of Dr. Osnabrugge and S3 Ventures' Brian R. Smith to its board of directors, aiming to bolster their strategic direction.
About the H?lo Thrombectomy System
The H?lo Thrombectomy System signifies a paradigm shift in clot removal methodologies. It features a patented dual-action mechanism that combines robust aspiration with advanced mechanical clot disruption. This design facilitates substantial efficiency through a small-profile catheter, allowing for streamlined single-pass procedures. The comprehensive nature of the H?lo system enhances not only patient care but also the overall physician experience.
About Endovascular Engineering, Inc.
Endovascular Engineering, Inc. is dedicated to redefining treatment for venous thromboembolism. As a forward-thinking innovator in the medical technology arena, E2 focuses on solutions that significantly improve the standard of care in clot removal.
The H?lo PE Thrombectomy System is currently designated for investigational use only and has not yet received commercial approval.
Frequently Asked Questions
What is the main purpose of the recent funding raised by E2?
The $42 million raised will advance the development of E2's innovative clot removal technology platform focusing on pulmonary embolism treatment.
Who are the primary investors in this Series B financing?
The investment round was co-led by 415 Capital and S3 Ventures, with participation from Panakès Partners, M&L Healthcare, and others.
What is the significance of the H?lo Thrombectomy System?
The H?lo Thrombectomy System is a cutting-edge device designed to efficiently remove blood clots in treating pulmonary embolism.
How does the funding impact E2's clinical trials?
The financing will help E2 complete patient enrollment for its pivotal trial evaluating the H?lo PE Thrombectomy System.
What is the future outlook for Endovascular Engineering?
With strong investor confidence and innovative technology, E2 is positioned to redefine treatment standards in venous thromboembolism care.
